NCT04727749 is a NA clinical trial of Therapy Dog Team Visit in Pain, sponsored by University of Saskatchewan.

Who is sponsoring NCT04727749?

NCT04727749 is sponsored by University of Saskatchewan.

What drugs are being tested in NCT04727749?

Interventions in NCT04727749: Therapy Dog Team Visit.

What condition does NCT04727749 study?

NCT04727749 studies Pain, Pain, Acute, Pain, Chronic, Pain, Intractable.

Is NCT04727749 still recruiting?

NCT04727749 is currently completed. Last updated 5 November 2021.

Are results published for NCT04727749?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-11-05 · How we verify

NCT04727749

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pawsitive Impacts of Therapy Dog Visits

Completed NA Results posted Last updated 5 November 2021

What this trial tests

NA trial testing Therapy Dog Team Visit in Pain in 211 participants. Completed in 20 September 2019.

Timeline

7 June 2019

Primary endpoint
20 September 2019

20 September 2019

Quick facts

Lead sponsor	University of Saskatchewan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	211
Start date	7 June 2019
Primary completion	20 September 2019
Estimated completion	20 September 2019
Sites	1 location across Canada

Drugs / interventions tested

Therapy Dog Team Visit

Conditions studied

Pain — all drugs for Pain →
Pain, Acute — all drugs for Pain, Acute →
Pain, Chronic — all drugs for Pain, Chronic →
Pain, Intractable — all drugs for Pain, Intractable →

Sponsor

University of Saskatchewan

Who can join

18 and older, any sex, with Pain or Pain, Acute. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants Stratified by Edmonton Symptom Assessment System (Revised Version) (ESAS-r) Pain Scores Primary · 20 minutes post visit

Participants Stratified by Pain scores Edmonton Symptom Assessment System (revised version) (ESAS-r) 11-point rating scale (scale of 0 to 10), in which higher ratings indicate worse outcomes, Pain Scores at 20 Minutes Post Visit.

Group	Value	95% CI
Therapy Dog Team Visit	50
No Therapy Dog Team Visit	43

Group	Value	95% CI
Therapy Dog Team Visit	7
No Therapy Dog Team Visit	7

Group	Value	95% CI
Therapy Dog Team Visit	3
No Therapy Dog Team Visit	13

Group	Value	95% CI
Therapy Dog Team Visit	5
No Therapy Dog Team Visit	3

Group	Value	95% CI
Therapy Dog Team Visit	7
No Therapy Dog Team Visit	11

Group	Value	95% CI
Therapy Dog Team Visit	7
No Therapy Dog Team Visit	7

Group	Value	95% CI
Therapy Dog Team Visit	4
No Therapy Dog Team Visit	4

Group	Value	95% CI
Therapy Dog Team Visit	9
No Therapy Dog Team Visit	4

Change in Pain Score Primary · Baseline visit compared to 20 minutes post-visit

Pain score using the Edmonton Symptom Assessment System (revised version) (ESAS-r) 11-point rating scale (scale of 0 to 10), in which higher ratings indicate worse outcomes.

Group	Value	95% CI
Therapy Dog Team Visit	-0.90	± 2.05
No Therapy Dog Team Visit	0.03	± 2.30

Number of Participants Stratified by Edmonton Symptom Assessment System (Revised Version) (ESAS-r) Anxiety Scores Secondary · 20 minutes post-visit

Participants Stratified by Edmonton Symptom Assessment System (revised version) (ESAS-r) 11-point rating scale (scale of 0 to 10), in which higher ratings indicate worse outcomes, Anxiety Scores at 20 Minutes Post Visit

Group	Value	95% CI
Therapy Dog Team Visit	55
No Therapy Dog Team Visit	45

Group	Value	95% CI
Therapy Dog Team Visit	3
No Therapy Dog Team Visit	7

Group	Value	95% CI
Therapy Dog Team Visit	6
No Therapy Dog Team Visit	13

Group	Value	95% CI
Therapy Dog Team Visit	11
No Therapy Dog Team Visit	8

Group	Value	95% CI
Therapy Dog Team Visit	4
No Therapy Dog Team Visit	6

Group	Value	95% CI
Therapy Dog Team Visit	8
No Therapy Dog Team Visit	9

Group	Value	95% CI
Therapy Dog Team Visit	1
No Therapy Dog Team Visit	3

Group	Value	95% CI
Therapy Dog Team Visit	5
No Therapy Dog Team Visit	2

Number of Participants Stratified by Edmonton Symptom Assessment System (Revised Version) (ESAS-r) Depression Scores Secondary · 20 minutes post-visit

Group	Value	95% CI
Therapy Dog Team Visit	51
No Therapy Dog Team Visit	55

Group	Value	95% CI
Therapy Dog Team Visit	5
No Therapy Dog Team Visit	7

Group	Value	95% CI
Therapy Dog Team Visit	5
No Therapy Dog Team Visit	7

Group	Value	95% CI
Therapy Dog Team Visit	7
No Therapy Dog Team Visit	7

Group	Value	95% CI
Therapy Dog Team Visit	7
No Therapy Dog Team Visit	5

Group	Value	95% CI
Therapy Dog Team Visit	4
No Therapy Dog Team Visit	5

Group	Value	95% CI
Therapy Dog Team Visit	6
No Therapy Dog Team Visit	1

Group	Value	95% CI
Therapy Dog Team Visit	0
No Therapy Dog Team Visit	2

Number of Participants Stratified by Edmonton Symptom Assessment System (Revised Version) (ESAS-r) Well-Being Scores Secondary · 20 minutes post-visit

Group	Value	95% CI
Therapy Dog Team Visit	14
No Therapy Dog Team Visit	15

Group	Value	95% CI
Therapy Dog Team Visit	5
No Therapy Dog Team Visit	6

Group	Value	95% CI
Therapy Dog Team Visit	8
No Therapy Dog Team Visit	8

Group	Value	95% CI
Therapy Dog Team Visit	12
No Therapy Dog Team Visit	12

Group	Value	95% CI
Therapy Dog Team Visit	12
No Therapy Dog Team Visit	11

Group	Value	95% CI
Therapy Dog Team Visit	26
No Therapy Dog Team Visit	26

Group	Value	95% CI
Therapy Dog Team Visit	6
No Therapy Dog Team Visit	7

Group	Value	95% CI
Therapy Dog Team Visit	7
No Therapy Dog Team Visit	7

Change in Blood Pressure Secondary · 20 minutes post-visit

Mean arterial blood pressure using a blood pressure cuff

Group	Value	95% CI
Therapy Dog Team Visit	1.01	± 10.7
No Therapy Dog Team Visit	-.04	± 8.07

Change in Heart Rate Secondary · 20 minutes post-visit

Radial pulse

Group	Value	95% CI
Therapy Dog Team Visit	.48	± 11.68
No Therapy Dog Team Visit	-.4	± 8.02

Change in Anxiety Score Secondary · Baseline visit compared to 20 minutes post-visit

Anxiety score is measured using the Edmonton Symptom Assessment System (revised version) (ESAS-r) 11-point rating scale (scale of 0 to 10), in which higher ratings indicate worse outcomes.

Group	Value	95% CI
Therapy Dog Team Visit	-1.13	± 2.46
No Therapy Dog Team Visit	-0.11	± 2.60

Change in Depression Score Secondary · Baseline visit compared to 20 minutes post-visit

Depression score using the Edmonton Symptom Assessment System (revised version) (ESAS-r) 11-point rating scale (scale of 0 to 10), in which higher ratings indicate worse outcomes.

Group	Value	95% CI
Therapy Dog Team Visit	-0.72	± 1.71
No Therapy Dog Team Visit	0.02	± 1.77

Change in Well-Being Score Secondary · Baseline visit compared to 20 minutes post-visit

Well-Being score using the Edmonton Symptom Assessment System (revised version) (ESAS-r) 11-point rating scale (scale of 0 to 10), in which higher ratings indicate worse outcomes.

Group	Value	95% CI
Therapy Dog Team Visit	-0.87	± 1.84
No Therapy Dog Team Visit	0.14	± 1.84

Sponsor's own description

The goal of this unique 18 month study is to better understand the experiences of pain patients in the Royal University Hospital (RUH) Emergency Department (ED), to create excellence in health care. The purpose is to measure the impact of visiting therapy dogs on reducing ED patient pain.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Outcomes of a controlled trial with visiting therapy dog teams on pain in adults in an emergency department.
Carey B, Dell CA, Stempien J, Tupper S, et al · · 2022 · cited 11× · PMID 35263346 · DOI 10.1371/journal.pone.0262599

Verify or expand the search:

Other recruiting trials for Pain

Currently open trials in the same condition.

NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting

Other University of Saskatchewan trials

Trials by the same sponsor.

NCT07433686 — Saskatoon Berry Juice for Muscle Recovery · NA · not yet recruiting
NCT07489469 — Effectiveness of an AI Scribe Compared to Routine Templates for Clinical Documentation in Orthopedic Consultations · NA · completed
NCT06946316 — Dairy vs Plant-based Beverages for Improving Bone Health During Exercise · NA · recruiting
NCT04276857 — Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer · NA · recruiting
NCT03401294 — Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04727749 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Saskatchewan
Last refreshed: 5 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04727749.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing